GoAI
Get started
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd.

ENLV

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.47

−$0.03 · -2.00%

Aug 21, 4:00 PM ET

ENLV company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

71

Undervalued

Momentum

20

Strong Down

Sentiment

38

Bearish

Risk resilience

27

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Oren Hershkovitz
Listed since
Jul 31, 2014
Employees
34

Market position

Day range

Current $1.47

52-week range

Current $1.47

Open
$1.49
Previous close
$1.50
Volume
157.53K
1.17× average
Average volume
134.09K
Average daily volume
Market cap
24.74M USD
Beta
1.47
Market reference 1
50-day average
$5.2771
-72.14% below average
200-day average
$11.9385
-87.69% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
0×
P/B (TTM)
0×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0×
Altman Z-score
1.58
Piotroski F-score
3 of 9

Financial statements

Income trends

Operating income

−15M USD+3.45%

Net income

1.24B USD+1.25B USD
Income trends across reported periods1.36B USD855.55M USD348.92M USD−157.72M USDOperating income, FY2021: −19.29M USDOperating income, FY2022: −25.8M USDOperating income, FY2023: −29.4M USDOperating income, FY2024: −15.54M USDOperating income, FY2025: −15M USDNet income, FY2021: −14.47M USDNet income, FY2022: −31.06M USDNet income, FY2023: −29.07M USDNet income, FY2024: −15.01M USDNet income, FY2025: 1.24B USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −19.29M USD. Operating income FY2022 −25.8M USD. Operating income FY2023 −29.4M USD. Operating income FY2024 −15.54M USD. Operating income FY2025 −15M USD. Net income FY2021 −14.47M USD. Net income FY2022 −31.06M USD. Net income FY2023 −29.07M USD. Net income FY2024 −15.01M USD. Net income FY2025 1.24B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold332K USD545K USD835K USD777K USD546K USD
Gross profit−332K USD−545K USD−835K USD−777K USD−546K USD
Research and development8.92M USD10.13M USD19.24M USD18.69M USD12.88M USD
Selling, general, and administrative5.69M USD4.91M USD6.14M USD6.7M USD6.24M USD
Operating expenses14.67M USD14.99M USD29.4M USD25.8M USD19.29M USD
Interest income792K USD1.07M USD1.57M USD835K USD120K USD
Interest expense13K USD13K USD14K USD5.26M USD328K USD
Depreciation and amortization332K USD545K USD835K USD777K USD546K USD
Operating income−15M USD−15.54M USD−29.4M USD−25.8M USD−19.29M USD
Net income1.24B USD−15.01M USD−29.07M USD−31.06M USD−14.47M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 4 misses, 1 met estimate
Average EPS surprise
+2826.99%
11 comparable reports
Latest EPS result
-3.45
Estimate -0.45 · Miss by 666.67%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates443.35283.38123.42-36.55Q4 '24BeatQ1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ1 '26MissQ3 '26Estimate
Q4 2024, reported Nov 29, 2024: actual -1.8, estimate -2.4, surprise +25.00%, Beat. Q1 2025, reported Mar 31, 2025: actual -3.45, estimate -2.4, surprise -43.75%, Miss. Q2 2025, reported May 30, 2025: actual -2.25, estimate -2.4, surprise +6.25%, Beat. Q3 2025, reported Aug 29, 2025: actual -1.2, estimate -2.4, surprise +50.00%, Beat. Q4 2025, reported Nov 14, 2025: actual -1.35, estimate -1.8, surprise +25.00%, Beat. Q1 2026, reported Mar 25, 2026: actual 410.25, estimate -1.29, surprise +31791.77%, Beat. Q1 2026, reported Mar 30, 2026: actual -3.45, estimate -0.45, surprise -666.67%, Miss. Q3 2026, reported Aug 24, 2026: actual —, estimate -0.31, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$15.00

920.41% upside
Past 12 months12-month forecastHigh $15.00Average $15.00Low $15.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

Recent analyst actions

3 institutions

ENLV news

defenseworld.net

Comparing BioStem Technologies (OTCMKTS:BSEM) and Enlivex Therapeutics (NASDAQ:ENLV)

BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two…

Read source
globenewswire.com

Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June

As of July 29, 2026, trading volume on the Rain protocol reached $860MM1 622% month-over-month growth in trading volume during July 2026 vs June 2026 Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd.…

Read source
globenewswire.com

Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones

Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT…

Read source
globenewswire.com

Enlivex Announces $400,000,000 Private Placement

Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into…

Read source
defenseworld.net

Reviewing Korro Bio (NASDAQ:KRRO) and Enlivex Therapeutics (NASDAQ:ENLV)

Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) and Korro Bio (NASDAQ: KRRO - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on…

Read source
globenewswire.com

Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion

Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN…

Read source

Corporate actions

Corporate action history

Stock split

Effective Jul 9, 2026

1:15

Stock split

Effective Mar 6, 2019

1:8

Stock split

Effective Sep 25, 2017

1:5

ENLV peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ENLV

research.disclaimer